First Light Asset Management LLC Has $9.91 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

First Light Asset Management LLC decreased its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 66.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 420,431 shares of the company’s stock after selling 836,854 shares during the period. Dyne Therapeutics comprises 0.9% of First Light Asset Management LLC’s portfolio, making the stock its 28th biggest position. First Light Asset Management LLC owned about 0.41% of Dyne Therapeutics worth $9,905,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after buying an additional 698 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after acquiring an additional 721 shares during the period. KBC Group NV increased its holdings in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock valued at $279,000 after acquiring an additional 1,249 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 11.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after purchasing an additional 2,265 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 0.5 %

DYN stock opened at $11.06 on Monday. The firm has a 50-day moving average price of $10.79 and a 200-day moving average price of $19.54. The stock has a market capitalization of $1.26 billion, a P/E ratio of -3.11 and a beta of 1.21. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analysts Set New Price Targets

DYN has been the topic of several research analyst reports. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price on the stock. Piper Sandler reduced their price target on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Finally, Scotiabank initiated coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.46.

Insider Activity at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold 6,237 shares of company stock worth $77,760 over the last three months. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.